展览10.4

注册权协议

本登记权协议 （本「协议 ”), 于2025年[•]日生效，由GlycoMimetics, Inc.，一间特拉华州公司（以下简称为“权益代理 ”），以及签署本协议的几位投资者（各自为“投资者”和他们各自的被允许转让方，合称为“投资者”). 在此使用的大写术语，且在此未另有定义的，应具有证券购买协议中公司和投资者方所订的相应含义，该协议日期为2024年10月28日（根据情况修订、重述、补充或以其他方式修改，统称为“购买协议”).

鉴于：

A.            根据购买协议的条款和条件，公司已同意向某些投资者发行，并且这些投资者已同意分别且非共同地购买，总金额达$[•]的(x)股份（即“股票”），和/或(y)预付权证（即“权证”），以购买普通股票，每项根据购买协议。 初始股份和预付测得授权行使的普通股票股份，这里统称为“该”初始股份公司普通股每股价值$0.001的股价（“”）和/或预付权证（“”普通股”）和（y）预付权证进行购股的担保条件，视情况而定。初始股票及预付测向发行普通股的股份可本定为“该”预购权证”）股份.”

B.             为了诱使投资者进入购买协议，公司已同意根据1933年美国证券法（经修订）及其相关规则和规定，或任何类似的后续法令（总称为「证券法」，以及适用的州证券法。

因此，根据本协议中包含的相互承诺，各方同意将上述背景资料纳入本协议，并且各方在其他方面如下达成协议: 鉴于本协议中包含的承诺和双方所订立的协定以及其他充分而有价值的考虑，公司和投资者在此确认已收到并承认足够的对价，特此同意如下：

根据本协议的目的，以下术语应具有以下含义：

(a)            “提交 截止日期”表示根据此处所需的首次注册声明，距离交割日期后第30个日历日，并且根据根据此处提交的任何新注册声明或其他注册声明，距离（i）公司被SEC指南允许提交相关新注册声明的日期后的第30个日历日以及（ii）公司意识到需要提交相关新注册声明的日期后的第30个日历日。

(b)            “Person「」表示任何个人或实体，包括但不限于任何公司、有限责任公司、协会、合伙组织、组织、业务、个人、政府或政治辖区或政府机构。

(c)            “注册,” “已登记,登记「指根据《证券法》的规定，准备并提交公司的一个或多个注册申报书，并提供持续发行证券的安排，以及美国证券交易委员会对该注册声明或生效的宣布或命令（即「美国证券交易委员会”).

(d)            “可登记的证券「股份」指（i）本股份， （ii）根据约当日由公司，Crescent Biopharma, Inc.， Gemini Merger Sub Corp.和Gemini Merger Sub II，LLC订定的某项合并和重组协议，在约当日或附近日期发行给投资者的任何普通股份，以及（iii）与上述因股份拆分或分割，股份股息，资本重组，兑换或类似事件有关而发行或可发行的任何普通股份。可登记证券将在以下事件最早发生时停止成为可登记证券（并且公司无需要求维护任何，或提交另一份，与之相关的登记声明以继续有效性）：（A）当投资者转售了登记声明涵盖的这些可登记证券的日期，（B）这些可登记证券已根据第144条规则被投资者先前出售，（C）这些证券符合第144条规则的投资者无需成交量或出售方式方面限制即可再次销售，公司无需遵守第144条规则下的当前公开信息要求，以及（D）本协议签署之日起五（5）年后。

(e)            “注册 费用“费用”表示公司为根据本协议进行的任何注册而发生的所有注册和备案费用，包括（i）所有注册、资格和备案费用、印刷费用以及与向SEC、FINRA或任何其他监管机构进行的备案有关的任何其他费用和开支、（ii）所有与遵守或为了根据任何证券或“蓝天”法律出售可登记证券而进行的费用和开支、（iii）所有印刷、复制、文字处理、传呼、电话、传真和交付费用，以及（iv）公司的律师费和所有公司独立注册会计师的费用和支出（包括任何特别审计和出具相信函所需的费用）；但公司绝不对任何投资者的承销、经纪或类似费用或佣金，或投资者在《购买协议》中未另行规定的任何法律费用或其他费用负责。

(f)            “注册声明书“注册声明” 指公司根据《证券法》向SEC注册或拟向SEC注册的任何注册声明， 其中包括注册可登记证券的相关初稿或最终招股说明书、修改和补充资料；前后生效修正案；以及注册声明中通过参考并入文中以符合适用证券法律而必要的所有展品和所有材料。"注册声明" 还包括一个新的注册声明，在其各自生效时进行的修改，包括作为其一部分提交的所有文件或通过引用纳入其中的文件，以及包括随后提交给SEC的招股说明书中包含的任何信息。

(g)            “SEC 指导“”表示（i）任何SEC工作人员公开发布的书面或口头指导，或SEC工作人员的任何评论、要求或要求（无论是否公开），但前提是SEC将任何此类口头指导、评论、要求转书面形式（如果未公开，应在投资者要求下与投资者分享），以及（ii）《证券法》。

(h)            “销售费用「券商折扣和销售佣金」指适用于可登记证券出售的所有折扣和佣金，以及与投资者处置其可登记证券相关的类似费用和佣金。

(a)            必须 注册公司应在合理可行的最短时间内，但绝不迟于提交期限，准备并向SEC备案一份首次注册声明（即“初始注册声明”），以覆盖所有可登记证券的转让。在提交注册声明之前，公司应向投资者提供一份注册声明副本。在提交注册声明之前，投资者及其各自的律师应至少有三（3）个工作日的时间来审阅并对该注册声明及对该注册声明的任何修订或补充以及相关招股说明书（其中包括任何被其引用的文件）提出意见。公司应（a）诚实考虑投资者或其律师合理提出的任何评论，并在该文件在向SEC提交前的文件，和（b）不在任何向投资者的信息的注册声明或相关招股说明书或任何修订或补充文件中包含欺诈陈述或未能载明必须在其中载明的事实或在其表述的轻视情况下使其表述在其制作时不具有误导性，除非（在公司意见下）该信息根据任何适用法律或法规或SEC指引要求。每位投资者应在本协议中提到的任何登记注册事项中合理要求的情况下向公司提供有关该投资者的所有信息。

(b)            有效性公司应尽商业上的合理努力，使初始注册声明及任何修正在最早可能日期被美国证券交易委员会宣布生效，但不迟于初始申报日期后的第六十（60）个日历日，如果美国证券交易委员会通知公司将“审查”初始注册声明，并在公司被美国证券交易委员会口头或书面通知（以较早者为准）的第五（5）个工作日之后确定该初始注册声明将不会“审核”或不会再受到进一步审查时（称为“有效性 截止日期”），公司应尽快通过电子邮件通知投资者，并在初始注册声明生效或补充后的二十四（24）小时内提供任何相关拟用于出售或处置与之相关的证券的招股说明书副本。公司应尽商业上的合理努力，根据证券法发布的第415条规定，使初始注册声明持续有效，并随时供投资者转售其中涵盖的所有可登记证券，直至以下事件中较早的发生日期：（i）投资者应已转售其中涵盖的所有可登记证券的日期；（ii）投资者可以根据第144条规定在无需注册的情况下转售可登记证券，并且不受任何成交量或销售方式限制的限制，并无需公司符合证券法第144条下的当前公众信息要求或任何类似规定的要求，以及（iii）本协议签订日期后五（5）年后的日期（注册期”）。初始注册声明（包括任何修正或补充及其中包含的招股说明书）不得包含任何重大事实的不实陈述或遗漏必须在其中陈述的重大事实，或在作出陈述时的情况下，未能使其，不违反法规。

(c)            注册股票数量充分在任何时间，初次注册声明可供认购证券的数量不足以覆盖可注册证券的情况下，公司应在必要和可允许的范围内修改初次注册声明或提交新的注册声明（以及其中的任何招股书或招股说明书，合称为“注册声明”），以尽快覆盖所有这些可注册证券，但在最迟提交期限之前。公司应尽商业上合理的努力，使此类修正和/或新注册声明在提交后尽快生效，但不得迟于（a）SEC通知公司将“审查”新的注册声明后的七十五（75）个日历日内的初次提交日期，或者（b）在公司收到SEC口头或书面通知之后的第五个（5）个工作日内，此通知较早，其中通知称新的注册声明将不被“审查”或不会再接受进一步审查。新的注册声明公司应尽商业合理努力确保此类修正和/或新注册声明在提交后尽快生效，但在提交之日起不迟于（a）新注册声明初次提交日期的七十五（75）个日历日，若SEC通知公司将“审查”新注册声明以及（b）公司口头或书面接到SEC通知的第五（5）个工作日内之早者。 第2条（a） 和 第2条（b）将适用于新的注册声明，但受此处修改。

(d)            可容许的 延迟在任何十二（12）个月的期间内，公司最多只能在不超过三十（30）连续天或总计不超过六十（60）天的情况下，可以延迟首次申报注册文件或任何其他注册文件的生效日期，或暂停使用任何注册文件中包含的招股说明书，前提是董事会经过合理判断，并根据法律顾问的建议，认为此类延迟或暂停是必要的，以（A）延迟披露涉及公司的重要非公开信息，包括与公司尚未达成的重要交易相关的信息，这将要求公司在注册文件中额外披露重要非公开信息，公司有保留为机密的正当业务目的，并且在董事会合理决定（在法律顾问的建议下），如果不披露该信息可能会导致注册文件不符合适用的披露要求；或者（B）修改或补充受影响的注册文件或相关招股说明书，以使该注册文件或招股说明书不包括重要事实的不实陈述或遗漏其中应该陈述的重要事实，或者使招股说明书的陈述在其制作时的情况下，不会误导（称为“允许延迟”); 在每种情况下，该B类股东和/或该B类股东的家庭成员需独立控制在此类帐户、计划或信托中持有的B类普通股实时；公司应当及时（a）书面通知每位投资者允许延迟的开始，但不得（未经投资者的书面同意）向投资者披露导致允许延迟的任何重要的非公开信息，（b）书面告知投资者在允许延迟结束之前停止适用注册文件下的所有销售，且（c）尽商业上的合理努力尽快终止允许的延迟。每位投资者可以发出书面通知（称为“退出通知向公司发出请求，要求不接收公司根据本 第2; 在每种情况下，该B类股东和/或该B类股东的家庭成员需独立控制在此类帐户、计划或信托中持有的B类普通股实时；, 公司对于以下情况，不应承担责任：根据第10（b）部分书面信息可靠地提供。部分要求的通知，该投资者可以随后书面撤销任何此类选择退出通知，该通知在收到后的五个工作日内生效。收到投资者的选择退出通知后（除非后来撤销），公司将不会向该投资者递送任何根据本 第2(d)部分的通知，该投资者将不再享有与任何该等通知相关的权利。

(e)            规则415；削减如果SEC随时认为在任何登记声明中的部分或全部可登记证券的发行不符合证券法第415条规定，不能延迟或连续进行发行(， 在每种情况下，该B类股东和/或该B类股东的家庭成员需独立控制在此类帐户、计划或信托中持有的B类普通股实时；, 公司对于以下情况，不应承担责任：根据第10（b）部分书面信息可靠地提供。公司应尽商业上合理的努力，与SEC倡导登记所有可登记证券)，或要求命名任何投资者为“承销商”，公司 应(i)立即通知每位可登记证券持有人此事，并(ii)尽商业上合理的努力说服 SEC，认为该登记声明所设想的发行是有效的二级发行，而不是根据第415规则定义的“由发行人”发行，且没有任何投资者是“承销商。” 每位投资者 有权由其法律顾问自费对本 第2(e)部分审核，并监督根据本 第2(e)部分的条款涉及的任何登记或事项，包括就相关事项提交给SEC的任何书面提交进行评论。 如果 即使公司尽商业上合理的努力并遵守本 当SEC拒绝修改其立场时，公司应（i）从注册声明中删除可注册证券的部分，和/ 或（ii）同意SEC可能要求的为确保公司符合规则415要求而进行的注册和可注册证券转售受限的限制和限制（统称，“SEC不修改其立场时，公司应（i）从注册声明中删除可注册证券的部分，和/ 或（ii）同意SEC可能要求的为确保公司符合规则415要求而进行的可注册证券注册和转售所需的限制和限制”SEC限制”); 在每种情况下，该B类股东和/或该B类股东的家庭成员需独立控制在此类帐户、计划或信托中持有的B类普通股实时；, 公司对于以下情况，不应承担责任：根据第10（b）部分书面信息可靠地提供。即公司不得未经投资者事先书面同意在该注册声明中将任何投资者列为“承销商”在每种情况下，该B类股东和/或该B类股东的家庭成员需独立控制在此类帐户、计划或信托中持有的B类普通股实时； 即，如果投资者不同意，则公司无需在任何涵盖其可注册证券的注册声明中包含该投资者的任何可注册证券，直至SEC不再要求将该投资者列为“承销商”或该投资者书面同意被列为“承销商”为止才有义务在其中包含投资者的可注册证券。根据本“第2(e)节”对投资者实施的任何减少 第2(e) 节中规定的任何减少分配应在投资者之间按比例分配，并首先适用于SEC指示的不能纳入或必须限制数量的任何投资者的可登记证券，然后再分配给所有其他投资者，除非SEC的限制另有要求或另有规定，或者投资者另有同意。

(f)             根据此处提交的每份注册声明应为工表S-3（但如果公司当时不符合在工表S-3上注册可转让证券的资格，则应根据本 第2(f)条）设立另一种表格进行注册。如果工表S-3无法用于转让可注册证券的注册，则公司应（i）在其他适当的表格上注册可注册证券的转让，（ii）承诺在工表S-3可用时尽快注册 在每种情况下，该B类股东和/或该B类股东的家庭成员需独立控制在此类帐户、计划或信托中持有的B类普通股实时； 公司应保持注册声明的有效性直至工表S-3涵盖的可注册证券已被SEC宣告有效之时。

就注册声明和任何可注册证券将要根据注册的情况而言 第2节在初始注册声明或任何新的注册声明上，公司应尽商业上的合理努力按照拟定的处置方式进行注册可登记证券，并据此公司应有以下义务：

(a)            通知书公司会及时通知投资者关于在SEC提交或生效的初次注册声明或任何新注册声明的后续修正（除了被引用的文件），或者其中是否已签发收据，或者任何拟补充招股书的后续补充，以及SEC要求对注册声明、任何新注册声明或任何招股书进行修正或补充，或者额外信息的任何请求。

(b)            修订公司将准备并向SEC提交任何修订、生效后修订或补充初步登记声明、任何新的注册声明或相关招股说明书，并根据需要发帖维持该登记声明的有效性，遵守证券法和交易法的规定，分配所有相关注册证券，或者在投资者和公司的合理意见下，根据投资者对注册证券进行的任何收购或销售而必要或建议的任何情况下进行。

(c)            投资者 审查公司不会对注册声明、任何新的注册声明或任何拟议中的投资者、可登记证券或本次交易相关的招股书进行任何修正或补充，除非（A）投资者及其法律顾问在提交给SEC之前至少提前三（3）个工作日获得通知并有机会对其进行审阅和评论，以及（B）公司已经合理考虑了投资者或其法律顾问提出的任何评论。

(d)            Copies Available. The Company will furnish to any Investor whose Registrable Securities are included in any Registration Statement and its counsel copies of the Initial Registration Statement, any prospectus thereunder (including all documents incorporated by reference therein), any prospectus supplement thereunder, any New Registration Statement and all amendments to the Initial Registration Statement or any New Registration Statement that are filed with the SEC during the Registration Period (including all documents filed with or furnished to the SEC during such period that are deemed to be incorporated by reference therein), each letter written by or on behalf of the Company to the SEC or the staff of the SEC, and each item of correspondence from the SEC or the staff of the SEC, in each case relating to such Registration Statement (other than any portion thereof which contains information for which the Company has sought confidential treatment) and such other documents as such Investor may reasonably request in order to facilitate the disposition of the Registrable Securities owned by such Investor that are covered by such Registration Statement, in each case as soon as reasonably practicable upon such Investor’s request and in such quantities as such Investor may from time to time reasonably request; provided, however, that the Company shall not be required to furnish any document to such Investor to the extent such document is available on EDGAR.

(e)            Notification of Stop Orders; Material Changes. The Company shall use commercially reasonable efforts to (i) prevent the issuance of any stop order or other suspension of effectiveness and, (ii) if such order is issued, obtain the withdrawal of any such order as soon as practicable. The Company shall advise the Investors promptly (but in no event later than 24 hours) and shall confirm such advice in writing, in each case: (i) of the Company’s receipt of notice of any request by the SEC or any other federal or state governmental authority for amendment of or a supplement to the Registration Statement or any prospectus or for any additional information; (ii) of the Company’s receipt of notice of the issuance by the SEC or any other federal or state governmental authority of any stop order suspending the effectiveness of the Initial Registration Statement or prohibiting or suspending the use of any prospectus or prospectus supplement, or any New Registration Statement, or of the Company’s receipt of any notification of the suspension of qualification of the Registrable Securities for offering or sale in any jurisdiction or the initiation or contemplated initiation of any proceeding for such purpose; and (iii) of the Company becoming aware of the happening of any event, which makes any statement of a material fact made in any Registration Statement or any prospectus untrue or which requires the making of any additions to or changes to the statements then made in any Registration Statement or any prospectus in order to state a material fact required by the Securities Act to be stated therein or necessary in order to make the statements then made therein (in the case of any prospectus, in light of the circumstances under which they were made) not misleading, or of the necessity to amend any Registration Statement or any prospectus to comply with the Securities Act or any other law. The Company shall not be required to disclose to the Investors the substance of specific reasons of any of the events set forth in clauses (i) through (iii) of the immediately preceding sentence (each, a “Suspension Event”), but rather, shall only be required to disclose that the event has occurred; provided that the Company shall not provide any material non-public information to the Investors in such notice. If at any time the SEC, or any other federal or state governmental authority shall issue any stop order suspending the effectiveness of any Registration Statement or prohibiting or suspending the use of any prospectus or prospectus supplement, the Company shall use its commercially reasonable efforts to obtain the withdrawal of such order at the earliest practicable time. The Company shall furnish to any Investor upon request, without charge, a copy of any correspondence from the SEC or the staff of the SEC, or any other federal or state governmental authority to the Company or its representatives relating to the Initial Registration Statement, any New Registration Statement or any prospectus, or prospectus supplement as the case may be. In the event of a Suspension Event set forth in clause (iii) of the second sentence of this Section ‎3(e), the Company will use its commercially reasonable efforts to publicly disclose such event as soon as reasonably practicable, or otherwise resolve the matter such that sales under Registration Statements may resume.

(f)            Confirmation of Effectiveness. If requested by an Investor at any time in respect of any Registration Statement, the Company shall deliver to such Investor a written confirmation (email being sufficient) from Company’s counsel of whether or not the effectiveness of such Registration Statement has lapsed at any time for any reason (including, without limitation, the issuance of a stop order) and whether or not such Registration Statement is currently effective and available to the Company for sale of Registrable Securities.

(g)            Listing. The Company shall use commercially reasonable efforts to cause all Registrable Securities covered by a Registration Statement to be listed on the Nasdaq Global Market and/or any other National Exchange upon which the Registrable Securities are listed.

(h)            Compliance. The Company shall otherwise use commercially reasonable efforts to comply with all applicable rules and regulations of the SEC under the Securities Act and the Exchange Act, including, without limitation, Rule 172 under the Securities Act, file any final prospectus, including any supplement or amendment thereof, with the SEC pursuant to Rule 424 under the Securities Act, promptly inform the Investor in writing if, at any time during the Registration Period, the Company does not satisfy the conditions specified in Rule 172 and, as a result thereof, the Investor is required to deliver a prospectus in connection with any disposition of Registrable Securities and take such other actions as may be reasonably necessary to facilitate the registration of the Registrable Securities hereunder, and make available to its security holders, as soon as reasonably practicable, but not later than the Availability Date (as defined below), an earnings statement covering a period of at least twelve (12) months, beginning after the effective date of each Registration Statement, which earnings statement shall satisfy the provisions of Section 11(a) of the Securities Act, including Rule 158 promulgated thereunder (for the purpose of this Section ‎3(h), “Availability Date” means the forty-fifth (45^th) day following the end of the fourth (4^th) fiscal quarter that includes the effective date of such Registration Statement, except that, if such fourth (4^th) fiscal quarter is the last quarter of the Company’s fiscal year, “Availability Date” means the ninetieth (90^th) day after the end of such fourth (4^th) fiscal quarter).

(i)            Blue-Sky. The Company shall use commercially reasonable efforts to register or qualify or cooperate with any Investor and its counsel in connection with the registration or qualification of such Registrable Securities for the offer and sale under the securities or blue sky laws of such jurisdictions reasonably requested by such Investor; provided, however, that the Company shall not be required in connection therewith or as a condition thereto to (i) qualify to do business in any jurisdiction where it would not otherwise be required to qualify but for this Section ‎3(i), (ii) subject itself to general taxation in any jurisdiction where it would not otherwise be so subject but for this Section ‎3(i), or (iii) file a general consent to service of process in any such jurisdiction.

(j)            Rule 144. With a view to making available to the Investors the benefits of Rule 144 (or its successor rule) and any other rule or regulation of the SEC that may at any time permit the Investors to sell shares of Common Stock to the public without registration, the Company covenants and agrees to use commercially reasonable efforts to make and keep adequate current public information available, as those terms are understood and defined in Rule 144, until the date as all of the Initial Shares may be sold without restriction by the holders thereof pursuant to Rule 144 or any other rule of similar effect (without the requirement for the Company to be in compliance with any current public information requirements). In addition for so long as any Registrable Securities are outstanding, the Company covenants and agrees to use commercially reasonable efforts to (i) file with the SEC in a timely manner all reports and other documents required of the Company under the Exchange Act; (ii) furnish electronically to each Investor upon request, as long as such Investor owns any Registrable Securities, (A) a written statement by the Company that it has complied with the reporting requirements of the Exchange Act, (B) a copy of or electronic access to the Company’s most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q, and (C) such other information as may be reasonably requested in order to avail such Investor of any rule or regulation of the SEC that permits the selling of any such Registrable Securities without registration, and (iii) provide any legal opinions.

(k)            Cooperation. The Company shall cooperate with the holders of the Registrable Securities to facilitate the timely preparation and delivery of certificates or uncertificated shares representing the Registrable Securities to be sold pursuant to such Registration Statement or Rule 144 free of any restrictive legends and representing such number of shares of Common Stock and registered in such names as the holders of the Registrable Securities may reasonably request in accordance with the provisions of the Purchase Agreement, and the Company may satisfy its obligations hereunder without issuing physical stock certificates through the use of The Depository Trust Company’s Direct Registration System.

(l)             Removal of Restrictive Legends. Without limiting Section 5.5 of the Purchase Agreement, the Company shall use commercially reasonable efforts to cause the Company’s transfer agent to remove any restrictive legend from any Registrable Securities, as promptly as practicable following effectiveness of the applicable Registration Statement, without any request for removal being required from any holder of Registrable Securities.

(a)            Investor Information. Each Investor shall provide a completed Investor Questionnaire in the form attached hereto as Exhibit A or such other form of questionnaire or information required by the Company in connection with the registration of the Registrable Securities within three (3) Business Days of request by the Company and no later than the end of the third (3rd) Business Day following the date on which such Investor receives draft materials in accordance with Section ‎2(a).

(b)            Suspension of Sales. Each Investor, severally and not jointly with any other Investor, agrees that, upon receipt of any notice from the Company of the existence of an Allowed Delay or Suspension Event, the Investor will promptly discontinue disposition of Registrable Securities pursuant to any Registration Statement covering such Registrable Securities until the Investor’s receipt of a notice from the Company confirming the resolution of such Allowed Delay or Suspension Event and that such dispositions may again be made.

(c)            Investor Cooperation. Each Investor, severally and not jointly with any other Investor, agrees to cooperate with the Company as reasonably requested by the Company in connection with the preparation and filing of any amendments and supplements to any Registration Statement or New Registration Statement hereunder, unless such Investor has notified the Company in writing of its election to exclude all of its Registrable Securities from such Registration Statement.

All Registration Expenses incurred in connection with registrations pursuant to this Agreement shall be borne by the Company. All Selling Expenses relating to securities registered on behalf of an Investor shall be borne by such Investor.

(a)            To the fullest extent permitted by law, the Company will, and hereby does, indemnify, hold harmless and defend each Investor, each Person, if any, who controls each Investor, the shareholders, directors, officers, partners, employees, members, managers, agents, representatives and advisors of each Investor and each Person, if any, who controls any of the foregoing within the meaning of the Securities Act or the Exchange Act (each, an “Indemnified Person”), against any losses, obligation, claims, damages, liabilities, contingencies, judgments, fines, penalties, charges and costs (including, without limitation, court costs and costs of preparation), reasonable and documented attorneys’ fees, amounts paid in settlement or reasonable and documented expenses (collectively, “Indemnified Damages”) reasonably incurred in investigating, preparing or defending any action, claim, suit, inquiry, proceeding, investigation or appeal taken from the foregoing by or before any court or governmental, administrative or other regulatory agency or body or the SEC, whether pending or threatened, whether or not an indemnified party is or may be a party thereto (“Claims”), to which any of them may become subject insofar as such Claims (or actions or proceedings, whether commenced or threatened, in respect thereof) arise out of or are based upon: (i) any untrue statement or alleged untrue statement or omission or alleged omission of any material fact contained in any Registration Statement, or (ii) any violation or alleged violation by the Company or any of its Subsidiaries of the Securities Act, Exchange Act or any other state securities or other “blue sky” laws of any jurisdiction in which Registrable Securities are offered or any rule or regulation promulgated thereunder applicable to the Company or its agents and relating to action or inaction required of the Company in connection with such registration of the Registrable Securities (the matters in the foregoing clauses (i) and (ii) being, collectively, “Violations”). The Company shall reimburse each Indemnified Person promptly as such Indemnified Damages are incurred and are due and payable, for any reasonable out-of-pocket legal fees or other reasonable and documented expenses incurred by them in connection with investigating or defending any such Claim. Notwithstanding anything to the contrary contained herein, the indemnification agreement contained in this Section ‎6(a): (A) shall not apply to a Claim by an Indemnified Person arising out of or based upon a Violation which occurs in reliance upon and in conformity with information furnished in writing to the Company by the Investors or such Indemnified Person specifically for use in such Registration Statement and was reviewed and approved in writing by such Investor or such Indemnified Person expressly for use in connection with the preparation of any Registration Statement; (B) with respect to any superseded prospectus, shall not inure to the benefit of any such Person from whom the Person asserting any such Claim purchased the Registrable Securities that are the subject thereof (or to the benefit of any other Indemnified Person) if the untrue statement or omission of material fact contained in the superseded prospectus was corrected in the revised prospectus, as then amended or supplemented, and the Indemnified Person was promptly advised in writing not to use the outdated, defective or incorrect prospectus prior to the use giving rise to a Violation; (C) shall not be available to the extent such Claim is based on a failure of the Indemnified Person to deliver, or cause to be delivered, if required the prospectus to the Persons asserting an untrue statement or omission or alleged untrue statement or omission at or prior to the written confirmation of the sale of Registrable Securities; and (D) shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the prior written consent of the Company, which consent shall not be unreasonably withheld, conditioned or delayed. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of the Indemnified Person and shall survive the transfer of the Registrable Securities by the Investor pursuant to Section ‎8.

(b)            In connection with the Initial Registration Statement, any New Registration Statement or any prospectus, each Investor, severally and not jointly, agrees to indemnify, hold harmless and defend, the Company, each of its directors, and officers who signed the Initial Registration Statement or signs any New Registration Statement, and each Person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act (each, an “Indemnified Party”), against any losses, claims, damages, liabilities and expense (including reasonable attorney fees) resulting from any untrue statement or alleged untrue statement or omission or alleged omission of any material fact contained in any Registration Statement or (ii) any violation or alleged violation by Investor of its obligations under this Agreement, in each case to the extent, and only to the extent, that such violation occurs in reliance upon and in conformity with information about such Investor furnished in writing by such Investor to the Company expressly for use in connection with the preparation of the Registration Statement, any New Registration Statement. In no event shall the liability of an Investor be greater in amount than the dollar amount of the proceeds (net of all expense paid by such Investor in connection with any claim relating to this Section ‎6 and the amount of any damages such Investor has otherwise been required to pay by reason of such untrue statement or omission) received by such Investor upon the sale of the Registrable Securities included in such Registration Statement giving rise to such indemnification obligation. Notwithstanding anything to the contrary contained herein, the indemnification agreement contained in this Section ‎6(b), shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the prior written consent of the such Investor, which consent shall not be unreasonably withheld, conditioned or delayed. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such Indemnified Party and shall survive the transfer of the Registrable Securities by an Investor pursuant to Section ‎8.

(c)            Promptly after receipt by an Indemnified Person or Indemnified Party under this Section ‎6 of notice of the commencement of any action or proceeding (including any governmental action or proceeding) involving a Claim, such Indemnified Person or Indemnified Party shall, if a Claim in respect thereof is to be made against any indemnifying party under this Section ‎6, deliver to the indemnifying party a written notice of the commencement thereof, and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume control of the defense thereof with counsel mutually satisfactory to the indemnifying party and the Indemnified Person or the Indemnified Party, as the case may be, and upon such notice, the indemnifying party shall not be liable to the Indemnified Person or the Indemnified Party for any legal or other expenses subsequently incurred by the Indemnified Person or the Indemnified Party in connection with the defense thereof; provided, however, that an Indemnified Person or Indemnified Party (together with all other Indemnified Persons and Indemnified Parties that may be represented without conflict by one counsel) shall have the right to retain its own counsel with the reasonable fees and expenses to be paid by the indemnifying party, if, in the reasonable opinion of counsel retained by the indemnifying party, the representation by such counsel of the Indemnified Person or Indemnified Party and the indemnifying party would be inappropriate due to actual or potential differing interests between such Indemnified Person or Indemnified Party and any other party represented by such counsel in such proceeding. The Indemnified Party or Indemnified Person shall cooperate with the indemnifying party in connection with any negotiation or defense of any such action or claim by the indemnifying party and shall furnish to the indemnifying party all information reasonably available to the Indemnified Party or Indemnified Person which relates to such action or claim. The indemnifying party shall keep the Indemnified Party or Indemnified Person fully apprised as to the status of the defense or any settlement negotiations with respect thereto. No indemnifying party shall be liable for any settlement of any action, claim or proceeding effected without its written consent, provided, however, that the indemnifying party shall not unreasonably withhold, delay or condition its consent. No indemnifying party shall, without the consent of the Indemnified Party or Indemnified Person, consent to entry of any judgment or enter into any settlement or other compromise unless such judgment or settlement (i) imposes no liability or obligation on, (ii) includes as an unconditional term thereof the giving of a complete, explicit and unconditional release from the party bringing such indemnified claims of all liability of the Indemnified Party or Indemnified Person in respect to or arising out of such claim or litigation in favor of, and (iii) does not include any admission of fault, culpability, wrongdoing, or wrongdoing or malfeasance by or on behalf of, the Indemnified Party or Indemnified Person. Following indemnification as provided for hereunder, the indemnifying party shall be subrogated to all rights of the Indemnified Party or Indemnified Person with respect to all third parties, firms or corporations relating to the matter for which indemnification has been made. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action shall not relieve such indemnifying party of any liability to the Indemnified Person or Indemnified Party under this Section ‎6, except to the extent that the indemnifying party is prejudiced in its ability to defend such action.

(d)            The indemnification required by this Section ‎6 shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received or Indemnified Damages are incurred. Any Person receiving a payment pursuant to this Section ‎6 which person is later determined to not be entitled to such payment shall return such payment (including reimbursement of expenses) to the person making it.

(e)            The indemnity agreements contained herein shall be in addition to (i) any cause of action or similar right of the Indemnified Party or Indemnified Person against the indemnifying party or others, and (ii) any liabilities the indemnifying party may be subject to pursuant to the law.

To the extent any indemnification by an indemnifying party is prohibited or limited by law, the indemnifying party agrees to make the maximum contribution with respect to any amounts for which it would otherwise be liable under Section ‎6 to the fullest extent permitted by law; provided, however, that: (i) no seller of Registrable Securities guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any seller of Registrable Securities who was not guilty of fraudulent misrepresentation; and (ii) contribution by any seller of Registrable Securities shall be limited in amount to the net amount of proceeds (net of all expenses paid by such holder in connection with any claim relating to this Section ‎7 and the amount of any damages such holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission) received by such seller from the sale of such Registrable Securities giving rise to such contribution obligation.

The Company shall not assign this Agreement or any rights or obligations hereunder (whether by operation of law or otherwise) without the prior written consent of the Investors holding a majority of the Registrable Securities then outstanding (determined as if all of the Pre-Funded Warrants then outstanding have been exercised in full without regard to any limitations on the exercise of such Pre-Funded Warrants) (voting together as a single class); provided, however, that in any transaction, whether by merger, reorganization, restructuring, consolidation, financing or otherwise, whereby the Company is a party and in which the Registrable Securities are converted into the equity securities of another Person, from and after the effective time of such transaction, such Person shall, by virtue of such transaction, be deemed to have assumed the obligations of the Company hereunder, the term “Company” shall be deemed to refer to such Person and the term “Registrable Securities” shall be deemed to include the securities received by the Investor in connection with such transaction unless such securities are otherwise freely tradable by the Investor after giving effect to such transaction, and the prior written consent of the Investors holding a majority of the Registrable Securities then outstanding (determined as if all of the Pre-Funded Warrants then outstanding have been exercised in full without regard to any limitations on the exercise of such Pre-Funded Warrants) shall not be required for such transaction. No Investor may assign its rights under this Agreement, other than to an affiliate of such Investor or to any other investment funds or accounts managed or advised by the investment manager who acts on behalf of the Investor, without the prior written consent of the Company. The provisions of this Agreement shall be binding upon and inure to the benefit of the Investor and its successors and permitted assigns.

The provisions of this Agreement, including the provisions of this sentence, may be amended, modified or supplemented, or waived only by a written instrument executed by (a) the Company and (b) the holders of a majority of the then outstanding Registrable Securities (determined as if all of the Pre-Funded Warrants then outstanding have been exercised in full without regard to any limitations on the exercise of such Pre-Funded Warrants) (voting together as a single class), provided that (i) any party may give a waiver as to itself, (ii) any amendment, modification, supplement or waiver that disproportionately and adversely affects the rights and obligations of any Investor relative to the comparable rights and obligations of the other Investors shall require the prior written consent of such adversely affected Investor or each Investor, as applicable, and (iii) any amendments to Section ‎6 or to the definitions of “Filing Deadline,” “Effectiveness Deadline,” or “Registration Period” shall require the written consent of each Investor. Notwithstanding the foregoing, a waiver or consent to depart from the provisions hereof with respect to a matter that relates exclusively to the rights of one or more Investors and that does not adversely directly or indirectly affect the rights of other Investors may be given by Investors holding a majority of the Registrable Securities (determined as if all of the Pre-Funded Warrants then outstanding have been exercised in full without regard to any limitations on the exercise of such Pre-Funded Warrants) to which such waiver or consent relates.

(a)            Notices. Any notices or other communications required or permitted to be given hereunder shall be in writing and shall be deemed to be given (a) when delivered if personally delivered to the party for whom it is intended, (b) when delivered, if sent by electronic mail during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient’s next business day, provided no rejection or undeliverable notice is received, (c) three (3) days after having been sent by certified or registered mail, return-receipt requested and postage prepaid, or (d) one (1) business day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day delivery, with written verification of receipt:

i.              If to the Company, addressed as follows:

GlycoMimetics, Inc.
9708 Medical Center Drive

Rockville, Maryland 20850

Attention: Christian Dinneen-Long

Email: cdinneen-long@glycomimetics.com

with a copy (which shall not constitute notice), prior to the Closing:

Sidley Austin, LLP
2850 Quarry Lake Drive, Suite 301
Baltimore, MD 21209
Attention: Asher Rubin
Email: arubin@sidley.com

with a copy (which shall not constitute notice), following the Closing:

Gibson, Dunn & Crutcher LLP
One Embarcadero Center, Suite 2600
San Francisco, CA 94111
Attention: Ryan Murr, Branden Berns; Chris Trester
Email: rmurr@gibsondunn.com, bberns@gibsondunn.com; ctrester@gibsondunn.com

ii.             If to any Investor, at its e-mail address or address set forth on Exhibit A to the Purchase Agreement or to such e-mail address, or address as subsequently modified by written notice given in accordance with this Section ‎10.

Any Person may change the address to which notices and communications to it are to be addressed by notification as provided for herein.

(b)            No Waiver. No failure or delay on the part of either party hereto in the exercise of any power, right or privilege under this Agreement shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude any other or further exercise thereof or of any other right, power or privilege.

(c)            Governing Law; Submission to Jurisdiction; Venue; Waiver of Trial by Jury. The provisions of Section 8.5 of the Purchase Agreement are incorporated by reference herein mutatis mutandis.

(d)            Integration. This Agreement and the other Transaction Agreements (including all schedules and exhibits hereto and thereto) constitute the entire agreement between the parties hereto respecting the subject matter hereof and thereof and supersedes all prior agreements, negotiations, understandings, representations and statements respecting the subject matter hereof and thereof, whether written or oral.

(e)            Headings. The titles, subtitles and headings in this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement.

(f)             Counterparts. This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile or pdf signature including any electronic signatures complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com shall be considered due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original, not a facsimile or pdf (or other electronic reproduction of a) signature.

(g)            Further Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

(h)            Contract Interpretation. This Agreement is the joint product of each Investor and the Company and each provision hereof has been subject to the mutual consultation, negotiation and agreement of such parties and shall not be construed for or against any party hereto.

(i)             No Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as expressly provided in this Agreement. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

(j)             Severability. If any part or provision of this Agreement is held unenforceable or in conflict with the applicable laws or regulations of any jurisdiction, the invalid or unenforceable part or provisions shall be replaced with a provision which accomplishes, to the extent possible, the original business purpose of such part or provision in a valid and enforceable manner, and the remainder of this Agreement shall remain binding upon the parties hereto.

(k)            Non-Recourse. Notwithstanding anything that may be expressed or implied in this Agreement, the Company covenants, agrees and acknowledges that no recourse under this Agreement or any documents or instruments delivered in connection with this Agreement shall be had against any current or future director, officer, employee, stockholder, general or limited partner or member of the Investors or of any affiliates or assignees thereof, whether by the enforcement of any assessment or by any legal or equitable proceeding, or by virtue of any statute, regulation or other applicable law, it being expressly agreed and acknowledged that no personal liability whatsoever shall attach to, be imposed on or otherwise be incurred by any current or future director, officer, employee, stockholder, general or limited partner or member of the Investors or of any affiliates or assignees thereof, as such for any obligation of the Investors under this Agreement or any documents or instruments delivered in connection with this Agreement for any claim based on, in respect of or by reason of such obligations or their creation.

(l)             Specific Performance. In addition to any and all other remedies that may be available at law in the event of any breach of this Agreement, each Investor shall be entitled to specific performance of the agreements and obligations of the Company hereunder and to such other injunction or equitable relief as may be granted by a court of competent jurisdiction.

(m)           Cumulative Remedies. The remedies provided herein are cumulative and not exclusive of any remedies provided by law.

[Signature Page Follows]

IN WITNESS WHEREOF, the parties have caused this Registration Rights Agreement to be duly executed as of date first written above.

[Signature Page to Registration Rights Agreement]

IN WITNESS WHEREOF, the parties have caused this Registration Rights Agreement to be duly executed as of date first written above.

[Signature Page to Registration Rights Agreement]

Exhibit A

Investor Questionnaire

The undersigned hereby provides the following information to the Company and represents and warrants that such information is accurate:

QUESTIONNAIRE

Yes ¨      No ¨

Yes ¨      No ¨

Yes ¨      No ¨

Yes ¨      No ¨

Except as set forth below in this Item 4, the undersigned is not the beneficial or registered owner of any securities of the Company other than the securities issuable pursuant to the Purchase Agreement.

The undersigned agrees to promptly notify the Company of any material inaccuracies or changes in the information provided herein that may occur subsequent to the date hereof at any time while the Registration Statement remains effective; provided, that the undersigned shall not be required to notify the Company of any changes to the number of securities held or owned by the undersigned or its affiliates.

By signing below, the undersigned consents to the disclosure of the information contained herein in its answers to Items 1 through 5 and the inclusion of such information in the Registration Statement and the related prospectus and any amendments or supplements thereto. The undersigned understands that such information will be relied upon by the Company in connection with the preparation or amendment of the Registration Statement and the related prospectus and any amendments or supplements thereto.

IN WITNESS WHEREOF the undersigned, by authority duly given, has caused this Notice and Questionnaire to be executed and delivered either in person or by its duly authorized agent.

PLEASE EMAIL A .PDF COPY OF THE COMPLETED AND EXECUTED QUESTIONNAIRE TO: